<DOC>
	<DOCNO>NCT02734706</DOCNO>
	<brief_summary>To investigate effect supplement capsule contain LRC™ ( L. reuteri NCIMB 30242 ) , take twice daily lunch dinner ( NLT 2.5E9 CFU per dose ) , versus placebo capsule serum low density lipoprotein ( LDL ) -cholesterol otherwise healthy hypercholesterolemic adult 9 week product consumption .</brief_summary>
	<brief_title>Efficacy LRC™ ( L. Reuteri NCIMB 30242 ) Capsule Managing Cholesterol Adults</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Males female age 20 75 year . LDLC ≥ 3.40 mmol/L visit V0 V21 ( &lt; 15 % variation visit V0 V21 ) . TG &lt; 4.00 mmol/L ( checked visit V0 V21 ) . BMI 23.0 32.5 kg/m2 . Subject understands accepts follow dietary recommendation advisable hypercholesterolemic patient ( accord NCEPATP III guideline ) Judged investigator compliant ( &gt; 80 % ) product consumption ( check V21 ) , motivate . Subjects take stable dos thyroid hormone antihypertensive agent permit , long continue equivalently throughout duration study . Agreement maintain current level physical activity throughout study . If female , subject child bear potential . Defined female hysterectomy oophorectomy , bilateral tubal ligation postmenopausal ( natural surgically &gt; 1 year since last menstruation ) OR Female subject childbearing potential must agree use medically approve method birth control negative urine pregnancy test result . Acceptable method birth control include Hormonal contraceptive include oral contraceptive , hormone birth control patch ( Ortho Evra ) , vaginal contraceptive ring ( NuvaRing ) , injectable contraceptive ( DepoProvera , Lunelle ) , hormone implant ( Norplant System ) ; Intrauterine device ; Vasectomy partner . Voluntary , write , inform consent participate study . Use cholesterol lower prescription drug within last 6 month . Use plant sterol , omega 3 , fish oil , soy protein , soluble oat fiber , psyllium seed husk , cholesterol lower nonprescription supplement within last 1 month . History chronic use alcohol ( &gt; 2 drinks/d ) . History heavy smoking ( ≥20 cigarettes/d ) . Use systemic antibody , corticosteroid , androgen , phenytoin . Immunecompromised subject ( e.g . AIDS , lymphoma , subject undergoing longterm corticosteroid treatment ) . Subject experience cardiovascular event ( myocardial infarction , coronary artery bypass , major surgical procedure ) last 6 month . Subjects elevate LDLC ( ≥ 3.40 mmol/L ) high ( &gt; 20 % ) CVD risk estimate Framingham risk score . Previously diagnose Type I Type II diabetes endocrine disorder adrenal insufficiency , Cushing 's disease , hyperthyroidism , hypopituitarism polycystic ovary syndrome . Subject receive systemic treatment topical treatment likely interfere evaluation study parameter . Subject currently involve clinical trial exclusion period follow participation another clinical trial . History angina , congestive heart failure , inflammatory bowel disease , pancreatitis , gastrointestinal , renal , pulmonary , hepatic biliary disease , cancer ( evidence active lesion , chemotherapy surgery past year ) . Clinically significant abnormal laboratory result screen . Chronic user probiotic fibre laxative ( great 2 doses/wk ) , stimulant laxative . History eat disorder . Exercise great 15 miles/wk 4,000 kcal/wk . For female subject : Pregnancy , breast feeding , intent get pregnant . Allergy sensitivity test product ingredient . Allergy sensitivity 3 antibiotic ( Clindamycin , Erythromycin Ampicillin ) . Diagnosis anemia bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>